Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison

John Wilding, Professor of medicine at the University of Liverpool

“For people living with obesity, the choice of treatment matters, and clinicians increasingly want evidence on how the available options compare.”

John Wilding, Professor of medicine at the University of Liverpool

“Tirzepatide 10 mg and 15 mg and semaglutide 1.7 mg and 2.4 mg were compared directly in SURMOUNT-5, where tirzepatide helped people with obesity lose more weight.”

John Wilding, Professor of medicine at the University of Liverpool

“In the absence of a head-to-head trial comparing tirzepatide 15 mg against semaglutide 7.2 mg, this indirect comparison offers useful evidence for physicians as they make treatment decisions.”

Thomas Seck, Senior vice president of product development, Lilly Cardiometabolic Health

“People with obesity have more treatment options than ever before, and their healthcare providers deserve as much information as possible to help guide their decisions.”

Thomas Seck, Senior vice president of product development, Lilly Cardiometabolic Health

“In a head-to-head Phase 3 clinical trial, Zepbound 10 mg and 15 mg delivered greater weight loss than Wegovy 1.7 mg and 2.4 mg, and a new indirect treatment comparison suggests the same doses of Zepbound may outperform Wegovy HD, as well.”

Thomas Seck, Senior vice president of product development, Lilly Cardiometabolic Health

“Together, these results offer physicians more information as they choose a treatment path.”